Turning Open-Label Extensions Into Engines of Real World Evidence
Open-label extensions (OLEs) have traditionally been viewed as a post-trial formality—an ethical mechanism to maintain patient access once a pivotal study concludes. But in today’s evidence landscape, that mindset is outdated. This article makes the case that OLEs can be strategically redesigned to serve as high-value engines of real-world evidence, bridging controlled clinical research with how therapies perform in routine practice.
Sponsors can design OLEs that move beyond passive follow-up to generate decision-grade insights on long-term safety, durability of response, treatment persistence, and comparative effectiveness. The article explores how integrating external real-world data sources, such as claims, EHRs, registries, and external control cohorts, can extend the analytic power of OLEs while maintaining continuity with the original trial population.
It also addresses what it takes to make these programs regulatory-ready, from pre-specified analytic plans and bias control to traceability, data governance, and patient-centered operations that sustain engagement over time. For real-world evidence leaders, this piece offers a practical framework for transforming OLEs from overlooked add-on studies into strategic assets that support submissions, market access, and long-term lifecycle value.
